Search Within

Robert Motzer

Formats
  1. Journal Article (609)
  2. Meeting Abstract (578)
  3. Book Section (20)
  4. Review (13)
  5. Correspondence (7)
  6. Conference Paper (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (3)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1248)
  2. Genitourinary Oncology Service (1248)
  3. Solid Tumor Oncology Division (1248)
  4. Surgery (290)
  5. Urology (281)
  6. Survivorship Research (253)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (31)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (448)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (451)
  2. Elsevier Science, Inc. (111)
  3. Oxford University Press (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (86)
  6. American Association for Cancer Research (58)

More Publishers

Results (1248)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Tannir, N. M.; Powles, T.; Escudier, B. J.; Donskov, F.; Grünwald, V.; Sternberg, C. N.; Schmidinger, M.; Schoffski, P.; Szczylik, C.; Peltola, K. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Pazopanib exposure response assessment as adjuvant therapy for patients with localized or locally advanced renal cell carcinoma (RCC) following nephrectomy
    Meeting Abstract

    Sternberg, C. N.; Donskov, F.; Haas, N. B.; Doehn, C.; Russo, P.; Elmeliegy, M.; Banerjee, H.; Aimone, P.; Voi, M.; Motzer, R. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to IMDC risk group
    Meeting Abstract

    Rini, B. I.; Hutson, T. E.; Figlin, R. A.; Lechuga, M.; Valota, O.; Serfass, L.; Casey, M.; Motzer, R. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Grünwald, V.; Hutson, T. E.; Porta, C.; Powles, T.; Eto, M.; Dutcus, C. E.; Baig, M. A.; Dutta, L.; Li, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma
    Meeting Abstract

    Miao, D.; Margolis, C.; Martini, D.; Mullane, S. A.; Cullen, D.; Horak, C.; Wind-Rotolo, M.; Hellmann, M. D.; Voss, M. H.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Histologic determinants of long-term overall survival in patients (pts) with germ cell tumors (GCT)
    Meeting Abstract

    Funt, S.; Patil, S.; Feldman, D. R.; Motzer, R. J.; Bajorin, D. F.; Sheinfeld, J.; Tickoo, S.; Reuter, V. E.; Bosl, G. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Donskov, F.; Motzer, R. J.; Voog, E.; Hovey, E. J.; Grüllich, C.; Nott, L. M.; Cuff, K. E.; Gil, T.; Jensen, N. V.; Chevreau, C.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
    Meeting Abstract

    Choueiri, T. K.; Rini, B. I.; Larkin, J. M. G.; Bjarnason, G. A.; Gravis, G.; Gurney, H.; Lee, J. L.; Keizman, D.; Haanen, J. B. A. G.; Tomita, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Discovery and prevalence of cancer-susceptibility germline mutations (Mts) in patients (Pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Carlo, M. I.; Mukherjee, S.; Kemel, Y.; Zhang, L.; Mandelker, D.; Vijai, J.; Coskey, D. T.; Pradhan, N.; Hyman, D. M.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (aRCC): Results from CheckMate 214, including overall survival by subgroups
    Meeting Abstract

    Motzer, R. J.; Tannir, N. M.; McDermott, D. F.; Frontera, O. A.; Melichar, B.; Plimack, E. R.; Barthelemy, P.; George, S.; Neiman, V.; Porta, C.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save